(Q36192738)

12 August 2017

1 reference

title

Statin response and pharmacokinetics variants (English)

1 reference

12 August 2017

1 reference

7

Ernst J Schaefer

1 reference

12 August 2017

Kouji Kajinami

1

1 reference

12 August 2017

Hiroshi Masuya

2

1 reference

12 August 2017

Yachiyo Hoshiba

3

1 reference

12 August 2017

Kenji Takeda

4

1 reference

12 August 2017

Ryoko Sato

5

1 reference

12 August 2017

Mizuho Okabayashi

6

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

Expert Opinion on Pharmacotherapy

12 August 2017

published in

1 reference

12 August 2017

volume

6

1 reference

12 August 2017

issue

8

1 reference

12 August 2017

page(s)

1291-1297

1 reference

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

A receptor-mediated pathway for cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Initial sequencing and analysis of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

The Sequence of the Human Genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Inheritance and drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

The genetic basis of variability in drug responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Safety considerations for statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Pharmacogenetic study of statin therapy and cholesterol reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Lipid-lowering response to statins is affected by CYP3A5 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

HMG-CoA reductase inhibitors and P-glycoprotein modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Novel statins: pharmacological and clinical results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Effects of fibrates on metabolism of statins in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1291

10.1517/14656566.6.8.1291

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference